SUMMARY Lymphokine activated killer (LAK) cells are a recently described cellular immune phenomenon with exciting potential for the treatment of tumours arising from solid organs. A comparison of some aspects of LAK cell precursors and LAK cell function was undertaken in 44 control subjects and 44 preoperative patients suffering from gastrointestinal cancer (20 localised and 24 advanced). Lymphokine activated killer cell precursor (natural killer (NK) cell) activity was significantly diminished in patients with advanced tumours (p<002) as was fully mature LAK cell activity against an NK resistant target cell (p<0-012). T-lymphocyte responses were not significantly different between the three groups. The reduced LAK cell generation was associated with a significantly diminished proliferative response of LAK precursors to stimulation with high dose IL-2 in vitro (p<0-012). lmpaired LAK cell generation may explain the failure of adoptive cellular immunotherapy with LAK cells in some patients with advanced gastrointestinal cancer and prompts the search for means of augmenting this activity in such patients.
SUMMARY Lymphokine activated killer (LAK) cells are a recently described cellular immune phenomenon with exciting potential for the treatment of tumours arising from solid organs. A comparison of some aspects of LAK cell precursors and LAK cell function was undertaken in 44 control subjects and 44 preoperative patients suffering from gastrointestinal cancer (20 localised and 24 advanced). Lymphokine activated killer cell precursor (natural killer (NK) cell) activity was significantly diminished in patients with advanced tumours (p<002) as was fully mature LAK cell activity against an NK resistant target cell (p<0-012). T-lymphocyte responses were not significantly different between the three groups. The reduced LAK cell generation was associated with a significantly diminished proliferative response of LAK precursors to stimulation with high dose IL-2 in vitro (p<0-012). lmpaired LAK cell generation may explain the failure of adoptive cellular immunotherapy with LAK cells in some patients with advanced gastrointestinal cancer and prompts the search for means of augmenting this activity in such patients.
Recurrent tumours of gastrointestinal origin are frequently resistant to conventional treatment with radiotherapy or chemotherapy. The recent reports on the successful use of adoptive cellular immunotherapy in patients with advanced solid organ malignancy have, however, rekindled interest in this approach.' l The principle of this treatment is to incubate large numbers of the patient's lymphocytes with high concentrations of the T-cell derived growth factor Interleukin-2 (IL-2) in vitro for several days.
This procedure yields a population of lymphoblasts which are highly cytotoxic against a wide variety of tumour cells, including autologous tumour, but not normal cells. These lymphokine activated killer (LAK) cells are then reinfused into the patient in high numbers together with IL-2 and have been shown to produce regression and in some cases cure, in most experimental animals and in a proportion of patients suffering from disseminated solid organ malignancy of a variety of origins.--Addrcss for corrcspondcncc: Mr P J Guillou, Univcrsity Dcpartment of Surgery, St James's Univcrsity Hospital, Lecds LS9 7TF.
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The almost universal success of this treatment in animals receiving syngeneic LAK cells (generated from healthy animals) contrasts with the failure of this treatment in about 50% of patients receiving autologous LAK cells.6 The study of these failures may provide insight into means of augmenting the efficacy of this procedure since we, and others, have previously shown that patients with advanced gastrointestinal cancer exhibit impaired specific and nonspecific immunological responses.7" More recently we have suggested that this may be a consequence of a failure of these patients' lymphocytes to generate adequate levels of the lymphokine IL-2.9 Interleukin-2 is known to positively regulate the expression of its own high affinity receptors"' and it may therefore be possible that LAK cell therapy fails in these patients because of their incapacity to generate a lymphocytotoxic response on exposure to exogenous lymphokine. The present investigations were designed to examine this possibility.
The term LAK cell is a functional denomination for cytotoxic lymphocytes whose phenotypic characteristics remain a matter of some controversy. Some workers suggest that LAK cell activity is subserved by lymphocytes whose precursors are natural killer (NK) cells."" "Others claim that the precursors are of T-lymphocyte iineage although they do not bind the classical markers of cytotoxic T-lymphocytes. ' -' 1 In this study we have examined some functional attributes of both T-lymphocytes and NK cells as well as LAK cell activity in patients with gastrointestinal cancer. In addition lymphocyte proliferation in response to IL-2 has also been measured.
Methods

PATI ENTS
Lymphocyte function was measured in three groups of individuals. Group 1 (controls) consisted of 44 patients suffering from non-malignant conditions (gall stones, peptic ulceration or peripheral vascular disease) admitted to the general surgical wards for operation. Forty four preoperative patients suffering from gastrointestinal cancer arising in the stomach, colon or rectum were also studied. Upon receipt of the surgical and pathological findings these patients were assigned either to the localised gastrointestinal cancer group (group 2) or were classified as suffering from advanced disease (group 3) without previous knowledge of the results of the lymphocyte function tests. Group 3 patients contained all those whose tumours were found to have breached the serosa or involved the regional lymph nodes, invaded local structures or had metastasised to the liver. Thus the only patients who were eligible for inclusion in group 2 were those with Dukes' stages A or B colorectal tumours or those with a mucosal gastric cancer. The final distribution of these patients is shown in the Table. LYMPHOCYTE PREPARATION Heparinised venous blood was obtained from all patients under study at the same time on the morning of operation before administration of any premedication. Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-hypaque centrifugation and corrected to a cell density of 1-5x107 cells/ml in RPMI 1640 medium containing gentamicin (160 ,ug/ml), Amphotericin (2-5 ,ug/ml), Natural killer activity was measured in these subjects using a four hour chromium release assay as previously described."'' The target cell used was the erythroleukemoid cell line K562. Briefly 5x 1( PBMC were incubated with 1(0 "chromium labelled K562 target cells in triplicate round bottomed microtitre plates in a total reaction volume of 200 Il in complete medium. Serial doubling dilutions of the effector cells were done so that the effector:target ratios ranged from 50:1 down to 6-25: 1. After four hours' incubation at 37°C in a humidified atmosphere of 5% CO2 in air, 100 tl of the supernatant were removed from each well and counted for radioactivity in a gamma counter. Spontaneous s'Cr-release and maximal 5'Cr incorporation were obtained by incubating 104 target cells alone in 200 tl medium without any effector cells or in the presence of 100 Il detergent respectively. The percentage specific 5'Cr-release at each effector: target cell ratio was then calculated according to the usual formula: Experimental release-spontaneous release x 100 Maximal release-spontaneous release T-lymphocyte stimulation with Concanavalin-A Peripheral blood mononuclear cells at l(0 cells/ml were distributed in 200 tl aliquots into 10 replicate wells of flat bottomed microtitre plates. Concanavalin A (20 ,tg/ml) was added to five of the wells and the plate was incubated at 37°C in a humidified atmosphere of 5% CO2 in air for 48 hours, with -`Hthymidine (1 [tCi/well) being added for the last 12 hours of culture. At the end of this period the cells were harvested and proliferation measured by counting the 'H-thymidine uptake in a beta counter. Thus for each patient studied the proliferation of unstimulated cells and Con-A stimulated cells was obtained in counts per minute and from these a stimulation index was calculated -that is, SI= H-Thymidine uptake in stimulated cells (cpm) S3H-Thymidine uptake in unstimulated cells (cpm) IL-2 activation of PBMC For each individual 20 millilitres complete medium containing 1-5x 10" PBMC per ml were prepared in 80 cm2 upstanding tissue culture flasks. To this cell suspension was added 200 units/ml of highly purified lectin free human lymphocyte derived Interleukin-2 (Lymphocult-HP, Biotest Pharma Gmbh, Frankfurt). This reagent is 950%) pure (Fig. 1) The mean basal NK activity exerted against the cell line K562 for all three study groups is summarised in Figure 1 . The mean (±SE) percentage cytotoxicity of control lymphocytes at an effector: target cell ratio of 50:1 was 32-1±2-26(%o. This was not significantly different from the corresponding mean figure of 37-7±3-98% for lymphocytes from the patients suffering from localised gastrointestinal cancer (t= 1-3, p=0-099, NS). The mean NK activity in control subjects, however, was significantly higher than that of patients suffering from advanced gastrointestinal cancer (23-25±3-2%, t=2-3, p=0-012) as was that of the patients suffering from localised disease (t=2-85, p=0(0034). At an effector:target cell ratio of 50:1 the mean activated NK activity against the K562 cell line was 69-1+4-36% for control subjects, 66-2+4-36% for patients with localised disease and 62-1+4-17% for patients with advanced GI cancer. None of these figures was significantly different from one another (Fig. 1) . Figure 2 reveals that the 'H-thymidine uptake of unstimulated lymphocytes from all three patient groups were not significantly different from one another indicating no increase or decrease in spontaneous lymphocyte proliferation in any of the three groups. Although there was a trend towards lower Concanavalin-A stimulated lymphocyte proliferation in the two cancer groups the mean responses were again not significantly different from those seen in the control subjects. This also is the case when these data are expressed as a stimulation index.
I YMPHOCYTE PROI IFERATION
These observations are in marked contrast to the proliferative responses observed for the lymphocytes exposed to pure IL-2 alone in vitro (Fig. 3) . The mean H-thymidine uptake (expressed as cpmxI (1 3 3H-thymidine uptake of cells from patients with advanced GI cancer was 13-74±2-52, this being significantly lower than that obtained for control subjects (t=2-59, p=0007) as well as that obtained for the patients with localised gastrointestinal cancer (t=2-0795, p=0-025).
LYMPHOKINE ACTIVATED KILLER (LAK) CELL
ACTIVITY
The mean (±2 SE) LAK cell activity at an effector:target cell ratio of 50:1 for each of the three subject groups is also displayed in Figure 3 . The mean LAK cell activity exerted by IL-2 stimulated lymphocytes from control subjects was 25-8+2.42% compared with a mean figure of 30-83+4-25% for lymphocytes from patients with localised GI cancer (t=0-715, p=0-24). In contrast the mean LAK activity for the lymphocytes obtained from patients suffering from advanced GI cancer was 16-8±4-23% which was significantly lower than both that of the control group (t=3-87, p=0.0001) and of those with localised disease (t=2-33, p=0012). . noteworthy, however, that even though the NK activity is diminished in patients with advanced disease, lymphokine activated killing of the NKsusceptible target cell K562 is almost identical in all three groups and suggests that these patients at least have the potential to generate higher levels of lymphocytotoxicity even if this is relatively diminished when these stimulated cells are confronted with an NK-resistant target cell -that is, exert impaired LAK activity.
An alternative view of LAK cell precursors is that they represcnt a T-lymphocyte which is quite distinct from classical cytotoxic T-lymphocytes.'3" If a generalised T-cell defect does exist in these patients, then this may also partially explain the failure of LAK cell generation in our group of patients with advanced disease. In the present study the proliferation of unstimulated T-cells is similar in all three groups but, although not statistically significant, the response to a T-cell mitogen is on average diminished in the two cancer groups. We have previously shown that a helper T-cell defect exists in these patients,9 and this may well influence other T-cell functions including T-cell-mediated LAK activity. As Overall, therefore, our data tend to the conclusion that it is a defect in the T-cell component of LAK precursors which is responsible for the impaired LAK activity which we report in the advanced cancer group. In view of the impaired basal NK activity in these patients, however, a proliferative and cytotoxic defect in this component of LAK activity cannot be excluded.
In conclusion, this investigation has revealed that LAK activity in patients with advanced gastrointestinal cancer is impaired compared with that observed in patients with localised disease and healthy control subjects. This impaired activity is associated with diminished proliferation of LAK precursors and may explain the failure of LAK/IL-2 therapy in patients with advanced gastrointestinal cancer. Further studies are required to dissect this defect in greater detail, with a view to identifying means of augmenting LAK activity in therapeutic protocols. 
